CF33-hNIS-antiPDL1. *moves mouse to x button to close tab* “But wait!” your writer screams from the page, “I promise it’s interesting!” Whilst I may not have the teaching prowess of Ms Frizzle, I implore you to stick around, because Imugene’s (ASX: IMU) immuno-oncology stuff is really interesting once you wrap your head around it. The
Read More
Since securing a European patent for their proprietary cancer vaccine HER-Vaxx, Imugene (ASX: IMU) have been busy. The Company has now announced the initiation of new clinical trials in collaboration with global pharmaceutical company, Merck & Co (NYSE: MRK). The USD $46 billion company will support Imugene in evaluating the efficacy and safety of HER-Vaxx
Read More
Cancer treatment is slowly shifting away from the standard chemo and radiation and more towards immunotherapy as an alternative treatment. Unlike chemotherapy which destroys healthy, rapidly dividing cells in the body, immunotherapy is more targeted, using the patient’s own immune system to fight cancer. Chemotherapy’s attack on healthy cells causes the well known side effects
Read More
Despite the many advances in cancer therapy, we still haven’t quite hit the nail on the head, with cancer still responsible for 12% of all deaths worldwide each year. The advancement of cancer therapies and the growing body of research is impressive to say the least, yet cancer patients of today do not fare much
Read More
Biopharma company Imugene (ASX: IMU) is now on their way towards commercialisation of their lung cancer treatment with approval from the US Food and Drug Administration (FDA) to commence human trials. With the project name PD1-Vaxx in the US, the approval enables Imugene to commence recruiting patients for a clinical trial of the treatment on
Read More